Article: Cytokinetics Raises $40M To Move Pipeline Products Along.

Staff Writer

Cytokinetics Inc. generated $40 million of working capital in closing its fifth round of financing, a preferred stock offering.

The privately held company said it would use the Series E funds to further its partnered clinical development program and advance additional programs into clinical work. South San Francisco-based Cytokinetics is focused on cytoskeletal drug discovery and development in the areas of oncology, cardiovascular disease and antifungal therapeutics.

"I think our success in this financing is a function of two key issues," Robert Blum, Cytokinetics' senior vice president of finance and corporate development and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!